Endoscopic Correction of VUR Using Vantris as a New Non-biodegradable Tissue Augmenting Substance: Three Years of Prospective Follow-up

Chertin, Boris; Arafeh, Wael Abu; Zeldin, Alexander; Ostrovsky, Israel A.; Kocherov, Stanislav

doi:10.1016/j.urology.2013.01.024

Cited by 34 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall success rate was 92.1% in this series. Recently, the results of three years of prospective follow up have been reported by the same group ( 23 ). Their success rate was 92.7% after a single injection in all grades of VUR and mean injected volume of PPC per ureter was 0, 7ml (range 0.1, 1ml).…”

Section: Discussionmentioning

confidence: 93%

The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux

et al. 2016

View full text Add to dashboard Cite

Purpose Subureteral injection of bulking agents in the endoscopic treatment of vesicoureteral reflux is widely accepted therapy with high success rates. Although the grade of vesicoureteric reflux and experience of surgeon is the mainstay of this success, the characteristics of augmenting substances may have an effect particularly in the long term. In this retrospective study, we aimed to evaluate the clinical outcomes of the endoscopic treatment of vesicoureteric reflux (VUR) with two different bulking agents: Dextranomer/hyaluronic acid copolymer (Dx/HA) and Polyacrylate polyalcohol copolymer (PPC).Materials and Methods A total 80 patients (49 girls and 31 boys) aged 1-12 years (mean age 5.3 years) underwent endoscopic subureteral injection for correction of VUR last six years. The patients were assigned to two groups: subureteral injections of Dx/HA (45 patients and 57 ureters) and PPC (35 patients and 45 ureters). VUR was grade II in 27 ureters, grade III in 35, grade IV in 22 and grade V in 18 ureters.Results VUR was resolved in 38 (66.6%) of 57 ureters and this equates to VUR correction in 33 (73.3%) of the 45 patients in Dx/HA group. In PPC group, overall success rate was 88.8% (of 40 in 45 ureters). Thus, Thus, this equates to VUR correction in 31 (88.5%) of the 35 patients.Conclusions Our short term data show that two different bulking agent injections provide a high level of reflux resolution and this study revealed that success rate of PPC was significantly higher than Dx/HA with less material.

show abstract

Section: Discussionmentioning

confidence: 93%

The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux

et al. 2016

View full text Add to dashboard Cite

show abstract

“…VUR was corrected in 92.7% and 4.2% of RRUs after the first and the second endoscopic injection of Vantris. Ureteral obstruction was recorded in two patients, resolved by insertion of stent in one case and open ureteral reimplantation in the other one [12].…”

Section: Discussionmentioning

confidence: 98%

“…In 2013, Chertin et al [12] reported 3 years of prospective follow-up with endoscopic injection of Vantris. A total of 109 children (37 males, 72 females) with 165 RRUs underwent the procedure.…”

Section: Discussionmentioning

confidence: 99%

Endoscopic correction of primary VUR by using polyacrylate polyalcohol copolymer (Vantris) in young girls: 2-Year follow-up

Sharifiaghdas

Tajalli

Otukesh

et al. 2014

Journal of Pediatric Urology

View full text Add to dashboard Cite

show abstract

“…The biodegradable nature of the Dx/HA copolymer and its role in long-term failures prompted development of the synthetic, non--biodegradable Polyacrylate Polyalcohol Copolymer (PPC, Vantris®) (41). PPC has had promising short and long-term results outside of the United States since its introduction in 2010 (42).…”

Section: Endoscopic Injectionmentioning

confidence: 99%

Evolving surgical management of pediatric vesicoureteral reflux: is open ureteral reimplantation still the ‘Gold Standard’?

Kirsch

Arlen

2020

Int. braz j urol.

View full text Add to dashboard Cite

Vesicoureteral refl ux, the retrograde fl ow of urine from the bladder into the upper urinary tract, is one of the most common urologic diagnoses in the pediatric population. Once detected, therapeutic options for urinary refl ux are diverse, ranging from observation with or without continuous low-dose prophylactic antibiotics to a variety of operative interventions. While a standardized algorithm is lacking, it is generally accepted that management be tailored to individual patients based on various factors including age, likelihood of spontaneous resolution, risk of subsequent urinary tract infections with renal parenchymal injury, and parental preference. Anti-refl ux surgery may be necessary in children with persistent refl ux, renal scarring or recurrent pyelonephritis after optimization of bladder and bowel habits. Open, laparoscopic/robotassisted and endoscopic approaches are all successful in correcting refl ux and have been shown to reduce the incidence of febrile urinary tract infections.

show abstract

Endoscopic Correction of VUR Using Vantris as a New Non-biodegradable Tissue Augmenting Substance: Three Years of Prospective Follow-up

Cited by 34 publications

References 6 publications

The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux

The outcomes of two different bulking agents (dextranomer hyaluronic acid copolymer and polyacrylate-polyalcohol copolymer) in the treatment of primary vesico-ureteral reflux

Endoscopic correction of primary VUR by using polyacrylate polyalcohol copolymer (Vantris) in young girls: 2-Year follow-up

Evolving surgical management of pediatric vesicoureteral reflux: is open ureteral reimplantation still the ‘Gold Standard’?

Contact Info

Product

Resources

About